Direct answer: The mouse experiments reviewed here reported effects on body weight, fat or metabolic measures. They do not provide a measured human before-and-after timeline. The original page incorrectly called the work one 2019 oral study and assigned it an 8-12-week timeline; the cited source is a 2018 mouse experiment, and a separate 2024 mouse study also exists.
5-Amino-1MQ results: separate the experiments
| Source | What was studied | Reported outcome | What it can answer |
|---|---|---|---|
| Neelakantan et al., 2018; PMID 29155147 | Diet-induced obese mice; subcutaneous treatment over 11 days | Reduced body weight and white adipose mass; smaller adipocytes; food intake did not change | Effects in that mouse experiment, not an oral human result |
| Babula et al., 2024; PMID 39161060 | Diet-induced obese mice, treated once daily for 28 days; separate pharmacokinetic experiments | Limited weight and fat-mass gains; improved glucose tolerance and insulin sensitivity; attenuated liver steatosis | Metabolic and body-composition outcomes in another mouse study |
| Awosemo et al., 2021; PMID 34304009 | Rats; analytical method and oral/intravenous pharmacokinetics | Reported oral bioavailability of 38.4% | Rat drug exposure, not a weight-loss result |
| Kraus et al., 2014; PMID 24717514 | NNMT gene knockdown in mice | Protection against diet-induced obesity | Target biology; gene knockdown is a different intervention from giving 5-Amino-1MQ |
Weight loss and reduced weight gain are different results
A treated group gaining less than a control group is not necessarily losing weight relative to its own starting point. The 2024 abstract describes limited body-weight and fat-mass gains. Reporting that as a universal percentage of weight lost would change the result.
Body weight, fat mass, adipocyte size and blood-glucose measures are also different endpoints. A result for one should not be relabeled as a result for another. The comparison above keeps the endpoint attached to the experiment.
How long did the research run?
The selected metabolic experiments ran for 11 days and 28 days. Those observation periods describe the animal experiments; they do not establish when a person would notice a change. The earlier 8-12-week claim was not an accurate account of the cited 2018 study.
From the FormBlends catalog
5-Amino-1MQ
NNMT inhibitor studied for metabolic aging and fat loss in research models · From $89/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about 5-Amino-1MQ →What Do 5-Amino-1MQ Before and After Pictures Actually Show?
Photographs circulating on social media, forums, and vendor pages showing before-and-after body composition changes attributed to 5-amino-1MQ share common confounds:
- No controlled comparator. Users are not randomized; they are self-selected and often changing diet and exercise simultaneously.
- Concurrent compounds. 5-amino-1MQ is frequently stacked with other research compounds (MOTS-c, GLP-1 agonists, stimulants) in user reports, making attribution impossible.
- Photography variables. Lighting, posture, timing relative to food and water intake, and pump from exercise are well-documented confounders in body composition photography.
- Publication bias. Positive-looking photos circulate; users who saw no change rarely post.
Before-and-after pictures should be treated as hypothesis-generating anecdote, not evidence of efficacy for any specific compound.
Is 5-Amino-1MQ a peptide?
No. It is a small-molecule NNMT inhibitor. Selling it alongside peptides does not change its chemical category. The 2014 target-knockdown paper and later compound-treatment experiments should also remain separate when evaluating the mechanism.
Does an absorption study prove fat loss?
No. The rat study measured exposure and bioavailability. It did not supply the human body-composition endpoint requested by a before-and-after question. For a comparison of the actual administration studies, see the oral-versus-injection evidence guide.
How to compare a new results claim with these studies
Identify the species or participant group, the intervention, the comparator, the duration and the measured endpoint. Then check whether the claim reports change from baseline or a difference versus a control. This distinguishes a documented experimental result from a timeline inferred from a product description.
Frequently asked questions
Was the cited research one oral mouse study from 2019?
No. The correctly linked Neelakantan paper is from 2018, and the comparison also includes the separate 2024 mouse work and 2021 rat pharmacokinetic study. They answer different questions.
Do these experiments measure muscle preservation in people?
No. The mouse body-composition findings and rat exposure measurements do not establish that endpoint in people.
Is 5-amino-1MQ legal to buy?
In the United States, 5-amino-1MQ is not FDA-approved as a drug or dietary supplement. It is sold as a research compound. Regulatory status varies by country. It is not a controlled substance under US federal law as of mid-2026, but legal status can change.
Known and Theoretical Risks of 5-Amino-1MQ
No human safety data from controlled studies exist. The following covers what is known and what is theoretically possible:
Animal safety signals: The Neelakantan 2018 study did not report observable adverse effects in its treated mice. However, this study was designed to measure metabolic outcomes, not as a formal toxicology assessment (no histopathology panel, no comprehensive organ function testing reported as primary endpoints).
Theoretical concern: methylation disruption. NNMT is one of the largest consumers of SAM in adipose tissue. Blocking it in adipose tissue raises local SAM, which sounds beneficial. But systemic NNMT inhibition could alter methylation reactions in other tissues that depend on SAM balance. Effects on DNA methylation, histone methylation, and neurotransmitter synthesis (which also uses SAM-dependent reactions) are theoretically possible with long-term systemic exposure. No evidence of this in published literature, but no long-term human data to rule it out either.
Drug interaction potential: Unknown. No published pharmacokinetic or drug-interaction studies exist for 5-amino-1MQ in humans.
Conflict of interest: FormBlends sells research compounds; claims on this page are graded against the evidence regardless of commercial interest.
Sources
- Neelakantan et al. NNMT inhibitor study in obese mice, 2018
- Babula et al. NNMT inhibition and metabolic dysfunction in mice, 2024
- Awosemo et al. Rat pharmacokinetics and oral bioavailability, 2021
- Kraus et al. NNMT knockdown, 2014
Related peptide guides
Ready when you are
5-Amino-1MQ
NNMT inhibitor studied for metabolic aging and fat loss in research models · From $89/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about 5-Amino-1MQ →